Design, Formulation and Evaluation of Pravastatin Fast Dissolving Tablets.

J. S. Kumar, R. Gunda
{"title":"Design, Formulation and Evaluation of Pravastatin Fast Dissolving Tablets.","authors":"J. S. Kumar, R. Gunda","doi":"10.5530/PHM.2018.1.4","DOIUrl":null,"url":null,"abstract":"Objective: The main objective of present research investigation is to formulate the Pravastatin Fast Dissolving tablets. Pravastatin, a newer antihyperlipidemic agent, belongs BCS class-III agent and used to treat hypercholesterolemia and to reduce the risk of Cardiovascular disease. Methods: The Fast Dissolving tablets of Pravastatin were prepared employing various concentrations of Crospovidone and Croscarmellose sodium in different combinations as a Superdisintegrants by Direct Compression technique using 32 factorial design. The concentration of Crospovidone and Croscarmellose sodium was selected as independent variables, X1 and X2 respectively whereas, wetting time, Disintegration time, t50% ,t90% were selected as dependent variables. Results and Discussion: Totally nine formulations were designed and are evaluated for hardness, friability, thickness, Assay, Wetting time, Disintegration time, In-vitro drug release. From the Results concluded that all the formulation were found to be with in the Pharmacopoeial limits and the In-vitro dissolution profiles of all formulations were fitted in to different Kinetic models, the statistical parameters like intercept (a), slope (b) & regression coefficient (r) were calculated. Polynomial equations were developed for Wetting time, Disintegration time, t50%, t90%. Validity of developed polynomial equations were verified by designing 2 check point formulations (C1, C2). According to SUPAC guidelines the formulation (F1) containing combination of 8% Crospovidone and 8% Croscarmellose, is the most similar formulation (similarity factor f2= 89.724, dissimilarity factor f1= 1.307 & No significant difference, t= 0.0465) to marketed product (PRAVACHOL-40). Conclusion: The selected formulation (F5) follows First order, Higuchi’s kinetics, mechanism of drug release was found to be NonFickian Diffusion Super Case-II Transport (n= 1.875).","PeriodicalId":19960,"journal":{"name":"Pharmaceutical Methods","volume":"47 1","pages":"16-23"},"PeriodicalIF":0.0000,"publicationDate":"2017-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"11","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceutical Methods","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5530/PHM.2018.1.4","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 11

Abstract

Objective: The main objective of present research investigation is to formulate the Pravastatin Fast Dissolving tablets. Pravastatin, a newer antihyperlipidemic agent, belongs BCS class-III agent and used to treat hypercholesterolemia and to reduce the risk of Cardiovascular disease. Methods: The Fast Dissolving tablets of Pravastatin were prepared employing various concentrations of Crospovidone and Croscarmellose sodium in different combinations as a Superdisintegrants by Direct Compression technique using 32 factorial design. The concentration of Crospovidone and Croscarmellose sodium was selected as independent variables, X1 and X2 respectively whereas, wetting time, Disintegration time, t50% ,t90% were selected as dependent variables. Results and Discussion: Totally nine formulations were designed and are evaluated for hardness, friability, thickness, Assay, Wetting time, Disintegration time, In-vitro drug release. From the Results concluded that all the formulation were found to be with in the Pharmacopoeial limits and the In-vitro dissolution profiles of all formulations were fitted in to different Kinetic models, the statistical parameters like intercept (a), slope (b) & regression coefficient (r) were calculated. Polynomial equations were developed for Wetting time, Disintegration time, t50%, t90%. Validity of developed polynomial equations were verified by designing 2 check point formulations (C1, C2). According to SUPAC guidelines the formulation (F1) containing combination of 8% Crospovidone and 8% Croscarmellose, is the most similar formulation (similarity factor f2= 89.724, dissimilarity factor f1= 1.307 & No significant difference, t= 0.0465) to marketed product (PRAVACHOL-40). Conclusion: The selected formulation (F5) follows First order, Higuchi’s kinetics, mechanism of drug release was found to be NonFickian Diffusion Super Case-II Transport (n= 1.875).
普伐他汀快溶片的设计、处方及评价。
目的:研制普伐他汀速溶片。普伐他汀是一种较新的抗高脂血症药物,属于BCS iii类药物,用于治疗高胆固醇血症和降低心血管疾病的风险。方法:采用32因子设计,采用直接压缩法,以不同浓度的交联维酮和交联棉糖钠作为超崩解剂,以不同的配比制备普伐他汀快溶片。分别以交联维酮和交联棉糖钠的浓度X1和X2为自变量,以润湿时间、崩解时间、t50%、t90%为因变量。结果与讨论:共设计了9种制剂,并对其硬度、脆度、厚度、含量、润湿时间、崩解时间、体外释放度进行了评价。结果表明,各制剂均符合药典标准,并拟合各制剂的体外溶出度曲线符合不同的动力学模型,计算其截距(a)、斜率(b)和回归系数(r)等统计参数。建立了润湿时间、崩解时间、t50%、t90%的多项式方程。通过设计2个检查点公式(C1, C2)验证了所建立的多项式方程的有效性。根据SUPAC指南,含有8% crosspovidone和8% crosscarmellose的配方(F1)与市售产品PRAVACHOL-40最相似(相似因子f2= 89.724,不同因子F1 = 1.307,无显著差异,t= 0.0465)。结论:所选制剂(F5)符合一级动力学,药物释放机制为非菲克扩散超级转运(n= 1.875)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信